Vitrolife Dirección

Dirección controles de criterios 2/4

El CEO de Vitrolife es Bronwyn Brophy O´Connor , nombrado en Aug 2023, tiene una permanencia de 1.25 años. compensación anual total es SEK7.44M, compuesta por 74.5% salario y 25.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.014% de las acciones de la empresa, por valor de €372.50K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 6.8 años, respectivamente.

Información clave

Bronwyn Brophy O´Connor

Chief Executive Officer (CEO)

SEK 7.4m

Compensación total

Porcentaje del salario del CEO	74.5%
Permanencia del CEO	1.3yrs
Participación del CEO	0.01%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bronwyn Brophy O´Connor en comparación con los beneficios de Vitrolife?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 4b
Jun 30 2024	n/a	n/a	-SEK 4b
Mar 31 2024	n/a	n/a	-SEK 4b
Dec 31 2023	SEK 7m	SEK 6m	-SEK 4b

Compensación vs. Mercado: La compensación total de Bronwyn($USD673.62K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD1.90M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Bronwyn con los resultados de la empresa.

CEO

Bronwyn Brophy O´Connor (50 yo)

1.3yrs

Permanencia

SEK 7,439,000

Compensación

Ms. Bronwyn Brophy O´Connor is President and Chief Executive Officer at Vitrolife AB (publ) since joining from August 01, 2023. She has an impressive track record as a leader of global Life science and Med...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Bronwyn Brophy O´Connor	CEO & President	1.3yrs	SEK 7.44m	0.014% € 372.5k
Patrik Tolf	Chief Financial Officer	2.8yrs	sin datos	0.0096% € 250.2k
Claus Bisgaard	Senior Vice President of Technologies	no data	sin datos	0.00028% € 7.3k
Guillermo Ferrando	Vice President Strategy & Corporate development	1.8yrs	sin datos	sin datos
Olivia Natens	Senior Vice President of Sales & Marketing	less than a year	sin datos	sin datos
Frank Pettersson	Acting Senior Vice President of HR & Sustainability	1.1yrs	sin datos	0.0013% € 34.1k
Rickard Ericsson	Senior Vice President of Consumables	less than a year	sin datos	0.0061% € 159.8k
Ricardo Capella	Senior Vice President Genetic Services	2.8yrs	sin datos	0.0044% € 115.5k

1.3yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VTFN no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Henrik Blomquist	Director	5.5yrs	SEK 883.00k	0.0081% € 211.7k
Jon Sigurdsson	Chairman of the Board	9.8yrs	SEK 16.30m	0.022% € 585.2k
Lars Holmqvist	Independent Director	6.8yrs	SEK 450.00k	sin datos
Pia Marions	Independent Director	11.6yrs	SEK 500.00k	0.0037% € 96.2k
Karen Soerensen	Independent Director	4.4yrs	SEK 500.00k	sin datos

6.8yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de VTFN se considera experimentada (6.8 años de antigüedad promedio).

Vitrolife Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Vitrolife AB (Publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Chief Financial Officer recently bought €47k worth of stock

Recent updates

Vitrolife AB (publ) to Report Fiscal Year 2024 Final Results on Mar 27, 2025

Vitrolife AB (publ) to Report Q4, 2025 Results on Jan 29, 2026

Third quarter 2024 earnings released: EPS: kr0.86 (vs kr0.90 in 3Q 2023)

Vitrolife AB (Publ) Announces Election Committee Appointments

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

Vitrolife AB (publ) to Report Q3, 2025 Results on Oct 29, 2025

Second quarter 2024 earnings released: EPS: kr1.06 (vs kr0.78 in 2Q 2023)

Now 19% undervalued after recent price drop

Now 19% undervalued after recent price drop

Now 20% undervalued after recent price drop

Vitrolife AB (publ) (OM:VITR) acquired Stb Zorg B.V.

Vitrolife AB (publ) (OM:VITR) signed an agreement to acquire Stb Zorg B.V. for €18 million.

Vitrolife AB (Publ) Approves Dividend for the Financial Year 2023

Upcoming dividend of kr1.00 per share

Now 24% undervalued

First quarter 2024 earnings released: EPS: kr0.85 (vs kr0.74 in 1Q 2023)

Dividend of kr1.00 announced

Full year 2023 earnings released: kr28.44 loss per share (vs kr2.91 profit in FY 2022)

Vitrolife AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Vitrolife AB (Publ) Reports Non-Cash Impairment for the Fourth Quarter of 2023

Now 20% undervalued

Third quarter 2023 earnings released: EPS: kr0.90 (vs kr0.80 in 3Q 2022)

Vitrolife AB (publ) Announces Election Committee Appointments

Vitrolife AB (publ) Announces Resignation of Maria Forss as Senior Vice President

Insufficient new directors

Vitrolife AB Announces Board Changes

Investor sentiment deteriorates as stock falls 18%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: kr0.78 (vs kr0.96 in 2Q 2022)

Vitrolife AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 15%

Chief Financial Officer recently bought €47k worth of stock

Upcoming dividend of kr0.85 per share at 0.4% yield

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Full year 2022 earnings released: EPS: kr2.91 (vs kr2.98 in FY 2021)

Vitrolife AB (publ) Proposes Dividend for 2022

Vitrolife AB (publ) Announces Executive Changes

Third quarter 2022 earnings released: EPS: kr0.80 (vs kr0.89 in 3Q 2021)

Vitrolife AB (publ) to Report First Half, 2023 Results on Jul 14, 2023

Vitrolife AB (publ) Announces Election Committee Appointments

Investor sentiment deteriorated over the past week

Now 20% undervalued after recent price drop

Vitrolife AB (Publ) Announces Retirement of Thomas Axelsson as CEO

Second quarter 2022 earnings released: EPS: kr0.96 (vs kr0.79 in 2Q 2021)

Vitrolife AB (publ), Annual General Meeting, Apr 27, 2023

Chief Financial Officer recently bought €48k worth of stock

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

First quarter 2022 earnings released: EPS: kr0.61 (vs kr1.09 in 1Q 2021)

Upcoming dividend of kr0.80 per share

Vitrolife AB (Publ) Proposes Dividend

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Vitrolife AB (Publ) Proposes Dividend

Third quarter 2021 earnings released: EPS kr0.89 (vs kr0.81 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.79 (vs kr0.11 in 2Q 2020)

Vitrolife AB (publ) Approves Dividend for the Financial Year 2020

First quarter 2021 earnings released: EPS kr1.09 (vs kr0.73 in 1Q 2020)

Upcoming dividend of kr0.80 per share

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Full year 2020 earnings released: EPS kr2.64 (vs kr3.53 in FY 2019)

Revenue misses expectations

New 90-day high: €22.60

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day low: €20.14

Third quarter 2020 earnings released: EPS kr0.81

Revenue beats expectations

Vitrolife AB (publ) to Report Fiscal Year 2020 Results on Mar 30, 2021

Vitrolife AB (publ) to Report Q1, 2021 Results on Apr 22, 2021

New 90-day low: €20.16